Mesoblast Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (25)

Latest Posts

About This Stock More About This Stock
Week In Review: Acletis Raising $457 Million In Hong Kong IPO At $2 Billion Valuation
Article By: ChinaBio® Today
Saturday, July 21, 2018 4:12 PM EST
Ascletis BioScience, the Hangzhou biopharma with a novel treatment for hepatitis C, may raise as much as $457 million in its upcoming Hong Kong IPO, a debut offering that values the company at $2 billion.
In this article: MESO
Read
Mesoblast - Chart Of The Day
Article By: Jim Van Meerten
Wednesday, March 8, 2017 11:26 PM EST
Since the Trend Spotter signaled a buy in 2/17 the stock gained 18.72%.
In this article: MESO
Read
Four Best Biotech Stocks Of The First Quarter Of 2016
Article By: Zacks Investment Research
Sunday, April 3, 2016 7:19 AM EST
The entry of the first FDA-approved biosimilar, Zarxio, a biosimilar version of Amgen’s blockbuster drug, Neupogent, last year has left biotech companies vying to enter this high revenue generating space. Biosimilars are the next big thing.
In this article: KIN, CRMD, ALIOF, MESO Also: AMGN, GILD, SHPG, BXLT
Read
Mesoblast IPO: A Chance To Take Off In The US
Article By: Don Dion
Monday, November 9, 2015 9:54 AM EST
Mesoblast Inc. (NASDAQ: MESO) expects to raise close to $70 million in its upcoming IPO. Mesoblast filed for the IPO on November 2, 2015.
In this article: MESO Also: JNJ, CELG, TEVA
Read

PARTNER HEADLINES

Latest Tweets for $MESO

No tweets yet!